Amneal Pharmaceuticals, Inc.

NYSE:AMRX Stock Report

Mkt Cap: US$643.6m

Amneal Pharmaceuticals Past Performance

How has Amneal Pharmaceuticals performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-26.7%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: AMRX is currently unprofitable.

Growing Profit Margin: AMRX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AMRX is unprofitable, and losses have increased over the past 5 years at a rate of 26.7% per year.

Accelerating Growth: Unable to compare AMRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AMRX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (7%).


Return on Equity

High ROE: AMRX has a negative Return on Equity (-124.34%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies